- Morley, John E;
- Abbatecola, Angela Marie;
- Argiles, Josep M;
- Baracos, Vickie;
- Bauer, Juergen;
- Bhasin, Shalender;
- Cederholm, Tommy;
- Coats, Andrew J Stewart;
- Cummings, Steven R;
- Evans, William J;
- Fearon, Kenneth;
- Ferrucci, Luigi;
- Fielding, Roger A;
- Guralnik, Jack M;
- Harris, Tamara B;
- Inui, Akio;
- Kalantar-Zadeh, Kamyar;
- Kirwan, Bridget-Anne;
- Mantovani, Giovanni;
- Muscaritoli, Maurizio;
- Newman, Anne B;
- Rossi-Fanelli, Filippo;
- Rosano, Giuseppe MC;
- Roubenoff, Ronenn;
- Schambelan, Morris;
- Sokol, Gerald H;
- Storer, Thomas W;
- Vellas, Bruno;
- von Haehling, Stephan;
- Yeh, Shing-Shing;
- Anker, Stefan D;
- Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop
A consensus conference convened by the Society of Sarcopenia, Cachexia and Wasting Disorders has concluded that "Sarcopenia, ie, reduced muscle mass, with limited mobility" should be considered an important clinical entity and that most older persons should be screened for this condition. "Sarcopenia with limited mobility" is defined as a person with muscle loss whose walking speed is equal to or less than 1 m/s or who walks less than 400 m during a 6-minute walk, and who has a lean appendicular mass corrected for height squared of 2 standard deviations or more below the mean of healthy persons between 20 and 30 years of age of the same ethnic group. The limitation in mobility should not clearly be a result of otherwise defined specific diseases of muscle, peripheral vascular disease with intermittent claudication, central and peripheral nervous system disorders, or cachexia. Clinically significant interventions are defined as an increase in the 6-minute walk of at least 50 meters or an increase of walking speed of at least 0.1 m/s.